proved that combination therapy with Atezolizumab (anti-PD-L1) plus Bevacizumab (anti-VEGF monoclonal antibody) increases OS and PFS of HCC patients and replaced as the primary chemotherapy line in advanced HCC patients (180). This evidence concerns the gene VEGFA and hepatocellular carcinoma.